News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Death Of Pfizer (PFE) Heart Drug Shows The Challenges Of CV R&D And Why Companies Are Bailing



11/2/2016 7:53:46 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Cardiovascular disease continues to be the world’s dominant killer. This is likely to continue to be the case, particularly as both obesity and diabetes, precursors to heart disease, continue to rise dramatically in the western world. Despite the fact that there are good drugs available to reduce LDL-cholesterol, blood pressure, etc., more advances are clearly needed. Yet, biopharmaceutical R&D investment appears to be waning.

One of the reasons for this can be found in Pfizer halting development of its PCSK9 inhibitor, bococizumab, a potent LDL-c-lowering agent for heart disease. This was not a trivial decision to take. Bococizumab was in the late stages of a clinical program which undoubtedly cost hundreds of millions of dollars.

Read at Forbes


comments powered by Disqus
Forbes
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES